Company intelligence / Profile preview
Tempero Bio
Oakland, California, United Statestemperobio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
TMP-301, the company's lead candidate, has been evaluated in over 80 healthy volunteers in Phase 1 trials with an acceptable safety and tolerability profile and demonstrated robust receptor occupancy via PET imaging. The company has initiated a Phase 2 trial for alcohol use disorder and plans to initiate studies for cocaine use disorder.
- Therapeutic areas
- Psychiatry
- Modalities
- Small moleculesmGluR5 negative allosteric modulators (NAMs)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Nxera Pharma (formerly Sosei Heptares)
Beyond the preview
Go deeper on Tempero Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tempero Bio.